Inhibitors Targeting the F-BOX Proteins.
E3 ligase
F-box protein
Ubiquitin
cancer progression
small molecule inhibitor
substrate
Journal
Cell biochemistry and biophysics
ISSN: 1559-0283
Titre abrégé: Cell Biochem Biophys
Pays: United States
ID NLM: 9701934
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
04
08
2023
medline:
30
10
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
F-box proteins are involved in multiple cellular processes through ubiquitylation and consequent degradation of targeted substrates. Any significant mutation in F-box protein-mediated proteolysis can cause human malformations. The various cellular processes F-box proteins involved include cell proliferation, apoptosis, invasion, angiogenesis, and metastasis. To target F-box proteins and their associated signaling pathways for cancer treatment, researchers have developed thousands of F-box inhibitors. The most advanced inhibitor of FBW7, NVD-BK M120, is a powerful P13 kinase inhibitor that has been proven to bring about apoptosis in cancerous human lung cells by disrupting levels of the protein known as MCL1. Moreover, F-box Inhibitors have demonstrated their efficacy for treating certain cancers through targeting particular mutated proteins. This paper explores the key studies on how F-box proteins act and their contribution to malignancy development, which fabricates an in-depth perception of inhibitors targeting the F-box proteins and their signaling pathways that eventually isolate the most promising approach to anti-cancer treatments.
Identifiants
pubmed: 37624574
doi: 10.1007/s12013-023-01160-1
pii: 10.1007/s12013-023-01160-1
doi:
Substances chimiques
F-Box Proteins
0
F-Box-WD Repeat-Containing Protein 7
0
Cell Cycle Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
577-597Subventions
Organisme : The postgraduate-education research programme of Zhengzhou university in 2021
ID : YJSJY202159
Organisme : National Natural Science Foundation of China
ID : 31900913
Organisme : National Natural Science Foundation of China
ID : NOs. 31900913, 82020108030, 81773562, 81703326 and 81973177
Organisme : National Key Research Program
ID : 2018YFE0195100
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bai, C., et al. (1996). SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell, 86(2), 263–274.
pubmed: 8706131
Wang, Z., et al. (2014). Roles of F-box proteins in cancer. Nature Reviews Cancer, 14(4), 233–247.
pubmed: 24658274
pmcid: 4306233
Kipreos, E. T., & Pagano, M. J. G. B. (2000). The F-box protein family. Genome Biology, 1, 1–7.
D’Angiolella, V., et al. (2010). SCF Cyclin F controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature, 466(7302), 138–142.
pubmed: 20596027
pmcid: 2946399
Duan, S., et al. (2012). FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature, 481(7379), 90–93.
pubmed: 22113614
pmcid: 3344385
Rye, M., et al. (2011). FBXO11, a regulator of the TGF β pathway, is associated with severe otitis media in Western Australian children. Genes & Immunity, 12(5), 352–359.
Santra, M. K., Wajapeyee, N., & Green, M. R. (2009). F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature, 459(7247), 722–725.
pubmed: 19412162
pmcid: 2722223
Skaar, J. R., Pagan, J. K., & Pagano, M. (2013). Mechanisms and function of substrate recruitment by F-box proteins. Nature Reviews Molecular cell biology, 14(6), 369–381.
pubmed: 23657496
Frescas, D., & Pagano, M. J. N. R. C. (2008). Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nature Reviews Cancer, 8(6), 438–449.
pubmed: 18500245
pmcid: 2711846
Lau, A. W., et al. (2014). The role of FBXW subfamily of F-box proteins in tumorigenesis. 15–45.
Nash, P., et al. (2001). Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature, 414(6863), 514–521.
pubmed: 11734846
Orlicky, S., et al. (2003). Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell, 112(2), 243–256.
pubmed: 12553912
Lau, A. W., et al. The role of FBXW subfamily of F-box proteins in tumorigenesis, in SCF and APC E3 Ubiquitin Ligases in Tumorigenesis. 2014, Springer. p. 15–45.
Busino, L., et al. (2003). Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature, 426(6962), 87–91.
pubmed: 14603323
Jin, J., et al. (2003). SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes & Development, 17(24), 3062–3074.
Watanabe, N., et al. (2004). M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proceedings of the National Academy of Sciences, 101(13), 4419–4424.
Wei, S., et al. (2008). A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. Journal of Biological Chemistry, 283(39), 26759–26770.
pubmed: 18650423
pmcid: 2546561
Sasajima, H., et al. (2012). Polyubiquitination of the B-cell translocation gene 1 and 2 proteins is promoted by the SCF ubiquitin ligase complex containing βTrCP. Biological and Pharmaceutical Bulletin, 35(9), 1539–1545.
pubmed: 22975506
Wojcik, E. J., Glover, D. M., & Hays, T. S. (2000). The SCF ubiquitin ligase protein slimb regulates centrosome duplication in Drosophila. Current Biology, 10(18), 1131–1134.
pubmed: 10996795
Zhou, B. P., et al. (2004). Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition. Nature Cell Biology, 6(10), 931–940.
pubmed: 15448698
Ray, D., Osmundson, E. C., & Kiyokawa, H. (2006). Constitutive and UV-induced fibronectin degradation is a ubiquitination-dependent process controlled by β-TrCP. Journal of Biological Chemistry, 281(32), 23060–23065.
pubmed: 16757476
Ding, Q., et al. (2007). Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Molecular and Cellular Biology, 27(11), 4006–4017.
pubmed: 17387146
Dehan, E., et al. (2009). βTrCP-and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Molecular Cell, 33(1), 109–116.
pubmed: 19150432
pmcid: 2655121
Tan, M., et al. (2006). SAG/ROC-SCFβ-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia, 8(12), 1042–1054.
pubmed: 17217622
pmcid: 1783718
Wang, Z., et al. (2012). Skp2: a novel potential therapeutic target for prostate cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1825(1), 11–17.
pubmed: 21963805
Hao, B., et al. (2005) Structural basis of the Cks1-dependent recognition of p27Kip1 by the SCFSkp2 ubiquitin ligase. 20(1): 9–19.
Kamura, T., et al. (2003). Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proceedings of the National Academy of Sciences, 100(18), 10231–10236.
Yu, Z.-K., Gervais, J. L., & Zhang, H. (1998). Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21CIP1/WAF1 and cyclin D proteins. Proceedings of the National Academy of Sciences, 95(19), 11324–11329.
Tedesco, D., Lukas, J., & Reed, S. I. (2002). The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein–ubiquitin ligase SCFSkp2. Genes & Development, 16(22), 2946–2957.
Hiramatsu, Y., et al. (2006). Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination. Cancer Research, 66(17), 8477–8483.
pubmed: 16951159
Huang, H., et al. (2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proceedings of the National Academy of Sciences, 102(5), 1649–1654.
Seki, R., et al. (2003). Prognostic significance of the F‐box protein Skp2 expression in diffuse large B‐cell lymphoma. American journal of Hematology, 73(4), 230–235.
pubmed: 12879424
Wang, H., et al. (2010). Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice. Nature Genetics, 42(1), 83.
pubmed: 19966802
Li, J.-Q., et al. (2004). Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. International Journal of Oncology, 25(1), 87–95.
pubmed: 15201993
Rose, A. E., et al. (2011). Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell & Melanoma Research, 24(1), 197–206.
Fang, F.-M., et al. (2009). Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. International Journal of Radiation Oncology* Biology* Physics, 73(1), 202–207.
pubmed: 18538504
Schüler, S., et al. (2011). SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. International Journal of Oncology, 38(1), 219–225.
pubmed: 21109943
Radke, S., Pirkmaier, A., & Germain, D. (2005). Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene, 24(21), 3448–3458.
pubmed: 15782142
Ma, X.-M., et al. (2005). Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World Journal of Gastroenterology: WJG, 11(42), 6716.
pubmed: 16425372
pmcid: 4355772
Wang, Z., et al. (2012). Skp2 is a promising therapeutic target in breast cancer. Frontiers in Oncology, 1, 57.
pubmed: 22279619
pmcid: 3263529
Kitagawa, M., Lee, S. H., & McCormick F. (2007). Skp2 suppresses p53-dependent apoptosis by inhibiting p300-mediated trans-activation. AACR.
Wu, L., et al. (2012). Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chemistry & Biology, 19(12), 1515–1524.
Nakayama, K., et al. (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Developmental Cell, 6(5), 661–672.
pubmed: 15130491
Chan, C.-H., et al. (2012). The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell, 149(5), 1098–1111.
pubmed: 22632973
pmcid: 3586339
Hershko, D. D. (2008). Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer, 112(7), 1415–1424.
pubmed: 18260093
Lin, H.-K., et al. (2009). Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nature Cell Biology, 11(4), 420–432.
pubmed: 19270694
pmcid: 2830812
Lin, H.-K., et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 464(7287), 374–379.
pubmed: 20237562
pmcid: 2928066
Zhang, S., (2011). Computer-aided drug discovery and development. Drug Design and Discovery 23–38.
Chan, C.-H., et al. (2013). Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell, 154(3), 556–568.
pubmed: 23911321
Zheng, X.-Y., et al. (2004). Correlation of Skp2 and P27kip1 protein expression and clinicopathological features of prostate cancer. Ai zheng= Aizheng= Chinese Journal of Cancer, 23(2), 215–218.
pubmed: 14960249
Schulman, B. A., et al. (2000). Insights into SCF ubiquitin ligases from the structure of the Skp1–Skp2 complex. Nature, 408(6810), 381–386.
pubmed: 11099048
Zheng, N., et al. (2002). Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex. Nature, 416(6882), 703–709.
pubmed: 11961546
Wen, Y., Wang, K., & Yang, K. (2016). Inhibiting the role of Skp2 suppresses cell proliferation and tumorigenesis of human gastric cancer cells via the upregulation of p27kip1. Molecular Medicine Reports, 14(4), 3917–3924.
pubmed: 27572672
Lin, S.-X., et al. (2010). Molecular therapy of breast cancer: progress and future directions. Nature Reviews Endocrinology, 6(9), 485–493.
pubmed: 20644568
Lu, Y., Zi, X., & Pollak, M. (2004). Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer, 108(3), 334–341.
pubmed: 14648698
Frankland-Searby, S., & Bhaumik, S. R. (2012). The 26S proteasome complex: an attractive target for cancer therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1825(1), 64–76.
pubmed: 22037302
Uddin, S., et al. (2008). Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Research, 68(9), 3379–3388.
pubmed: 18451165
Mackay, H., et al. (2005). A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clinical Cancer Research, 11(15), 5526–5533.
pubmed: 16061869
Park, E.-J., et al. (2013). Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells. Food and Chemical Toxicology, 55, 424–433.
pubmed: 23333577
Voutsadakis, I. A. (2008). The ubiquitin-proteasome system in colorectal cancer. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1782(12), 800–808.
pubmed: 18619533
Chen, Q., et al. 441 Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama 442 KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF (Skp2) results in p27-443 and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 111, 4690–4699.
Bochis, O. V., et al. (2015). The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer. Journal of Gastrointestinal & Liver Diseases, 24(2), 225–234.
Liao, Y., et al. (2014). Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death & Disease, 5(3), e1137–e1137.
Su, J., et al. (2016). Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. American Journal of Cancer Research, 6(9), 1949.
pubmed: 27725901
pmcid: 5043105
Huang, H.-C., Lin, C.-L., & Lin, J.-K. (2011). 1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. Journal of Agricultural and Food Chemistry, 59(12), 6765–6775.
pubmed: 21598989
Li, X., et al. (2015). Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget, 6(39), 41809.
pubmed: 26497688
pmcid: 4747190
Jiang, W., Lin, M., & Wang, Z. (2020). Dioscin: A new potential inhibitor of Skp2 for cancer therapy. EBioMedicine, 51, 102593.
pubmed: 31901855
pmcid: 6948171
Lee, H., et al. (2006). Mouse emi1 has an essential function in mitotic progression during early embryogenesis. Molecular and Cellular Biology, 26(14), 5373–5381.
pubmed: 16809773
pmcid: 1592703
Min, K.-W., et al. (2013). Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. International Journal Gynecological Pathology, 32(1), 3–14.
Lehman, N. L., et al. (2007). Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. American Journal Pathology, 170(5), 1793–1805.
Visintin, R., Prinz, S., & Amon, A. (1997). CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science, 278(5337), 460–463.
pubmed: 9334304
Sivakumar, S., & Gorbsky, G. J. (2015). Spatiotemporal regulation of the anaphase-promoting complex in mitosis. Nature Reviews Molecular Cell Biology, 16(2), 82–94.
pubmed: 25604195
pmcid: 4386896
Rahimi, H., et al. (2015). The expression pattern of APC2 and APC7 in various cancer cell lines and AML patients. Advances in Medical Sciences, 60(2), 259–263.
pubmed: 26046517
VanGenderen, C., Harkness, T. A. A., & Arnason, T. G. (2020). The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression. Aging (Albany NY), 12(15), 15818.
pubmed: 32805721
pmcid: 7467358
Machida, Y. J., & Dutta, A. (2007). The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes & Development, 21(2), 184–194.
Sailo, B. L., et al. (2019). FBXW7 in cancer: what has been unraveled thus far? Cancers, 11(2), 246.
pubmed: 30791487
pmcid: 6406609
Tu, K., et al. (2013). Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PloS One, 8(7), e68574.
pubmed: 23840897
pmcid: 3698167
Sato, M., et al. (2015). MYC is a critical target of FBXW7. Oncotarget, 6(5), 3292.
pubmed: 25669969
Wei, W., et al. (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell, 8(1), 25–33.
pubmed: 16023596
Sancho, R., et al. (2013). Fbw7 repression by hes5 creates a feedback loop that modulates Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biology, 11(6), e1001586.
pubmed: 23776410
pmcid: 3679002
Yokobori, T., et al. (2014). FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Molecular Cancer Research, 12(1), 32–37.
pubmed: 24165483
Ren, H., et al. (2013). The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Letters, 338(2), 229–238.
pubmed: 23562472
pmcid: 3750077
Welcker, M., & Clurman, B. E. (2007). Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Division, 2(1), 1–13.
Tang, X., et al. (2007). Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination. Cell, 129(6), 1165–1176.
pubmed: 17574027
Flugel, D., Gorlach, A., & Kietzmann T. (2011). Glycogen synthase kinase-3beta regulates cell growth, migration and angiogenesis via Fbw7 and USP-28-dependent degradation of hypoxia-inducible factor-1alpha. Blood.
Cao, J., Ge, M.-H., & Ling Z.-Q. (2016). Fbxw7 tumor suppressor: a vital regulator contributes to human tumorigenesis. Medicine. 95(7).
Isobe, T., et al. (2009). Adenovirus E1A inhibits SCFFbw7 ubiquitin ligase. Journal of Biological Chemistry, 284(41), 27766–27779.
pubmed: 19679664
pmcid: 2788827
Mao, J.-H., et al. (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature, 432(7018), 775–779.
pubmed: 15592418
Calcagno, D. Q., et al. (2013). MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterology, 13(1), 1–10.
Kimura, T., et al. (2003). hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Science, 94(5), 431–436.
pubmed: 12824889
Li, Z., et al. (2015). p53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Molecular Cancer Research, 13(3), 584–591.
pubmed: 25512615
Balamurugan, K., & Sterneck, E. (2013). The many faces of C/EBPδ and their relevance for inflammation and cancer. International Journal of Biological Sciences, 9(9), 917.
pubmed: 24155666
pmcid: 3805898
Gery, S., et al. (2005). C/EBPδ expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene, 24(9), 1589–1597.
pubmed: 15674331
Welcker, M., & Clurman, B. E. (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews Cancer, 8(2), 83–93.
pubmed: 18094723
Lu, K. P., & Zhou, X. Z. (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nature Reviews Molecular Cell Biology, 8(11), 904–916.
pubmed: 17878917
Min, S.-H., et al. (2012). Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Molecular Cell, 46(6), 771–783.
pubmed: 22608923
pmcid: 3389221
Wang, L., et al. (2014). Aberrant regulation of FBW7 in cancer. Oncotarget, 5(8), 2000.
pubmed: 24899581
pmcid: 4039140
Jiang, X., et al. (2012). Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells, 30(7), 1313–1326.
pubmed: 22553175
Wang, Q., et al. (2011). Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene, 30(36), 3875–3886.
pubmed: 21460851
Lerner, M., et al. (2011). MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle, 10(13), 2172–2183.
pubmed: 21597324
Panka, D. J., et al. (2008). GSK-3β inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. Journal Biological Chemistry, 283(2), 726–732.
Konopleva, M., et al. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Research, 68(9), 3413–3420.
pubmed: 18451169
pmcid: 4096127
Cragg, M. S., et al. (2009). Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nature Reviews Cancer, 9(5), 321–326.
pubmed: 19343035
Nijhawan, D., et al. (2003). Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes & Development, 17(12), 1475–1486.
Liu, Y., & Mallampalli, R. K. Small molecule therapeutics targeting F-box proteins in cancer. in Seminars in Cancer Biology. 2016. Elsevier.
Yan, L., et al. (2020). Emerging roles of F-box proteins in cancer drug resistance. Drug Resistance Updates, 49, 100673.
pubmed: 31877405
Xiao, Y., et al. (2018). FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. Molecular Oncology, 12(6), 883–895.
pubmed: 29633504
pmcid: 5983212
Feng, C., Yang, F., & Wang, J. (2017). FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation. Cancer Gene Therapy, 24(8), 342–347.
pubmed: 28776569
Kang, J.-H., et al. (2017). Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer. Oncotarget, 8(47), 83100.
pubmed: 29137327
pmcid: 5669953
Qie, S., et al. (2019). Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nature Communications, 10(1), 1–15.
Lian, Z., et al. (2015). FBXO4 loss facilitates carcinogen induced papilloma development in mice. Cancer Biology & Therapy, 16(5), 750–755.
Yoshida, A., et al. (2019). SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 5(9), eaax6352.
pubmed: 31555743
pmcid: 6750908
Tekcham, D. S., et al. (2020). F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Theranostics, 10(9), 4150.
pubmed: 32226545
pmcid: 7086354
Shima, Y., et al. (2008). PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. Molecular and Cellular Biology, 28(23), 7126–7138.
pubmed: 18809579
pmcid: 2593379
Chen, B. B., et al. (2013). A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nature Immunology, 14(5), 470–479.
pubmed: 23542741
pmcid: 3631463
Shao, W., et al. (2016). FBXO3 protein promotes ubiquitylation and transcriptional activity of AIRE (autoimmune regulator). Journal of Biological Chemistry, 291(34), 17953–17963.
pubmed: 27365398
pmcid: 5016183
Li, D., et al. (2015). F-box protein Fbxo3 targets Smurf1 ubiquitin ligase for ubiquitination and degradation. Biochemical and Biophysical Research Communications, 458(4), 941–945.
pubmed: 25721664
Kogure, N., et al. (2017). Low expression of FBXO45 is associated with gastric cancer progression and poor prognosis. Anticancer Research, 37(1), 191–196.
pubmed: 28011490
Siepka, S. M., et al. (2007). Circadian mutant Overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell, 129(5), 1011–1023.
pubmed: 17462724
pmcid: 3762874
Yamanaka, I., et al. (2007). Presence of robust circadian clock oscillation under constitutive over-expression of mCry1 in rat-1 fibroblasts. FEBS Letters, 581(21), 4098–4102.
pubmed: 17686474
Godinho, S. I., et al. (2007). The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science, 316(5826), 897–900.
pubmed: 17463252
Busino, L., et al. (2007). SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science, 316(5826), 900–904.
pubmed: 17463251
Huber, A.-L., et al. (2016). CRY2 and FBXL3 cooperatively degrade c-MYC. Molecular Cell, 64(4), 774–789.
pubmed: 27840026
pmcid: 5123859
Correia, S. P., et al. (2019). The circadian E3 ligase complex SCF FBXL3+ CRY targets TLK2. Scientific Reports, 9(1), 1–9.
Fuchs, S. Y., Spiegelman, V. S., & Kumar, K. S. (2004). The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene, 23(11), 2028–2036.
pubmed: 15021890
Margottin-Goguet, F., et al. (2003). Prophase destruction of Emi1 by the SCFβTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Developmental Cell, 4(6), 813–826.
pubmed: 12791267
Wei, X., et al. (2018). SKP2 promotes hepatocellular carcinoma progression through nuclear AMPK-SKP2-CARM1 signaling transcriptionally regulating nutrient-deprived autophagy induction. Cellular Physiology and Biochemistry, 47(6), 2484–2497.
pubmed: 29991055
Dorrello, N. V., et al. (2006). S6K1-and ßTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science, 314(5798), 467–471.
pubmed: 17053147
Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-κB and IKK function. Nature Reviews Molecular Cell Biology, 8(1), 49–62.
pubmed: 17183360
Chen, Z. J. (2005). Ubiquitin signalling in the NF-κB pathway. Nature Cell Biology, 7(8), 758–765.
pubmed: 16056267
pmcid: 1551980
Yaron, A., et al. (1998). Identification of the receptor component of the IκBα–ubiquitin ligase. Nature, 396(6711), 590–594.
pubmed: 9859996
Nakajima, H., et al. (2008). A novel small-molecule inhibitor of NF-κB signaling. Biochemical and Biophysical Research Communications, 368(4), 1007–1013.
pubmed: 18275844
Nakayama, K., et al. (2003). Impaired degradation of inhibitory subunit of NF-κB (IκB) and β-catenin as a result of targeted disruption of the β-TrCP1 gene. Proceedings of the National Academy of Sciences, 100(15), 8752–8757.
Yang, H.-S., et al. (2003). The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Molecular and Cellular Biology, 23(1), 26–37.
pubmed: 12482958
pmcid: 140682
Blees, J. S., et al. (2012). Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1. PloS one, 7(10), e46567.
pubmed: 23056346
pmcid: 3462793
Peterson, T. R., et al. (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 137(5), 873–886.
pubmed: 19446321
pmcid: 2758791
Duan, S., et al. (2011). mTOR generates an auto-amplification loop by triggering the βTrCP-and CK1α-dependent degradation of DEPTOR. Molecular cell, 44(2), 317–324.
pubmed: 22017877
pmcid: 3212871
Wang, Z., et al. (2012). DEPTOR ubiquitination and destruction by SCFβ-TrCP. American Journal of Physiology-Endocrinology and Metabolism, 303(2), E163–E169.
pubmed: 22454292
pmcid: 3431131
Zhao, Y., Xiong, X., & Sun, Y. (2011). DEPTOR, an mTOR inhibitor, is a physiological substrate of SCFβTrCP E3 ubiquitin ligase and regulates survival and autophagy. Molecular Cell, 44(2), 304–316.
pubmed: 22017876
pmcid: 3216641
Sakamoto, K. M., et al. (2001). Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences, 98(15), 8554–8559.
Sakamoto, K. M., et al. (2003). Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Molecular & Cellular Proteomics, 2(12), 1350–1358.
Schneekloth, A. R., et al. (2008). Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters, 18(22), 5904–5908.
O’Connor, L., et al. (1998). Bim: a novel member of the Bcl‐2 family that promotes apoptosis. The EMBO Journal, 17(2), 384–395.
pubmed: 9430630
pmcid: 1170389
Fletcher, J. I., & Huang, D. C. (2008). Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle, 7(1), 39–44.
pubmed: 18196961
Rogers, G. C., et al. (2009). The SCFSlimb ubiquitin ligase regulates Plk4/Sak levels to block centriole reduplication. Journal of Cell Biology, 184(2), 225–239.
pubmed: 19171756
pmcid: 2654306
Cunha-Ferreira, I., et al. (2009). The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Current Biology, 19(1), 43–49.
pubmed: 19084407
Bornstein, G., et al. (2003). Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. Journal of Biological Chemistry, 278(28), 25752–25757.
pubmed: 12730199
Carrano, A. C., et al. (1999). SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biology, 1(4), 193–199.
pubmed: 10559916
Bhattacharya, S., et al. (2003). SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene, 22(16), 2443–2451.
pubmed: 12717421
Yeh, K.-H., et al. (2001). The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. Biochemical and Biophysical Research Communications, 281(4), 884–890.
pubmed: 11237742
Von Der Lehr, N., et al. (2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Molecular Cell, 11(5), 1189–1200.
pubmed: 12769844
Yao, F., et al. (2018). SKP2-and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. Nature Communications, 9(1), 1–16.
Clement, E., et al. (2018). Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Science Signaling, 11(521), eaao3810.
pubmed: 29535262
pmcid: 5902813
Strohmaier, H., et al. (2001). Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature, 413(6853), 316–322.
pubmed: 11565034
Mao, J.-H., et al. (2008). FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science, 321(5895), 1499–1502.
pubmed: 18787170
pmcid: 2849753
Close, V., et al. (2019). FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood, The Journal of the American Society of Hematology, 133(8), 830–839.
Pine, S. R. (2018). Rethinking Gamma-secretase Inhibitors for Treatment of Non–small-Cell Lung Cancer: Is Notch the Target? Rethinking Gamma Secretase Inhibitors. Clinical Cancer Research, 24(24), 6136–6141.
pubmed: 30104200
pmcid: 6295228
Gao, J., et al. (2014). Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget, 5(11), 3444.
pubmed: 24899509
pmcid: 4116494
Babaei-Jadidi, R., et al. (2011). FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. Journal of Experimental Medicine, 208(2), 295–312.
pubmed: 21282377
pmcid: 3039859
Zhang, Z. & Richmond A. (2021). The role of PI3K inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors. Frontiers in Molecular Biosciences, 286.
Su, S., et al. (2022). PLK1 inhibition-based combination therapies for cancer management. Translational Oncology, 16, 101332.
pubmed: 34973570
Gutteridge, R. E. A., et al. (2016). Plk1 inhibitors in cancer therapy: from laboratory to clinics. Molecular Cancer Therapeutics, 15(7), 1427–1435.
pubmed: 27330107
pmcid: 4936921
Mori, A., et al. (2018). FBXW 7 modulates malignant potential and cisplatin‐induced apoptosis in cholangiocarcinoma through NOTCH 1 and MCL 1. Cancer Science, 109(12), 3883–3895.
pubmed: 30302867
pmcid: 6272118
Yada, M., et al. (2004). Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7. The. EMBO Journal, 23(10), 2116–2125.
pubmed: 15103331
pmcid: 424394
Gergely, P. A., et al. (2019). Tyrosine kinase inhibitor imatinib mesylate alters DMBA-induced early onco/suppressor gene expression with tissue-specificity in mice. BioMed Research International, 2019, 8670398.
Suenaga, M., et al. (2013). Influence of gefitinib and erlotinib on apoptosis and C-MYC expression in H23 lung cancer cells. Anticancer Research, 33(4), 1547–1554.
pubmed: 23564796
Lee, E. K., et al. (2013). The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Molecular and Cellular Biology, 33(22), 4422–4433.
pubmed: 24019069
pmcid: 3838190
Achkar, I. W., et al. (2018). Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. Journal of Translational Medicine, 16(1), 1–12.
Roy, S., et al. (2018). p38 MAPK pathway and its interaction with TRF2 in cisplatin induced chemotherapeutic response in head and neck cancer. Oncogenesis, 7(7), 1–16.
Liu, K., et al. (2013). Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell International, 13(1), 1–8.
Qie, S., et al. (2017). Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nat Commun, 8, 1534.
pubmed: 29142209
pmcid: 5688124
Wang, B., et al. (2021). circNRIP1 facilitates keloid progression via FXR1-mediated upregulation of miR-503-3p and miR-503-5p. International Journal of Molecular Medicine, 47(5), 1–13.
pubmed: 33448313
Peng, J., et al. (2018). An Hsp20-FBXO4 axis regulates adipocyte function through modulating PPARγ ubiquitination. Cell Reports, 23(12), 3607–3620.
pubmed: 29925002
Lin, D. I., et al. (2006). Phosphorylation-dependent ubiquitination of cyclin D1 by the SCFFBX4-αB crystallin complex. Molecular Cell, 24(3), 355–366.
pubmed: 17081987
pmcid: 1702390
Braal, C. L., et al. (2021). Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs, 81(3), 317–331.
pubmed: 33369721
Andrzejewski, S., et al. (2017). PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metabolism, 26(5), 778–787.e5.
pubmed: 28988825
Qie, S., et al. (2019). Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nature Communications, 10(1), 1296.
pubmed: 30899002
pmcid: 6428878
D’Angiolella, V., et al. (2012). Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell, 149(5), 1023–1034.
pubmed: 22632967
pmcid: 3616325
Fu, J., et al. (2013). Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Science, 104(4), 508–515.
pubmed: 23305207
pmcid: 7657186
Emanuele, M. J., et al. (2011). Global identification of modular cullin-RING ligase substrates. Cell, 147(2), 459–474.
pubmed: 21963094
pmcid: 3226719
Walter, D., et al. (2016). SCF (cyclin F)-dependent degradation of CDC6 suppresses DNA re-replication. Nat Commun, 7, 10530.
pubmed: 26818844
pmcid: 4738361
Altomonte, J., et al. (2003). Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. American Journal of Physiology Endocrinology and Metabolism, 285(4), E718–E728.
pubmed: 12783775
Haeusler, R. A., Kaestner, K. H., & Accili, D. J. J. O. B. C. (2010). FoxOs function synergistically to promote glucose production. Journal of Biologcal Chemistry, 285(46), 35245–35248.
Langlet, F., et al. (2017). Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell, 171(4), 824–835.e18.
pubmed: 29056338
pmcid: 5687849
Pandey, A., et al. (2016). FoxO1 inhibitors: the future medicine for metabolic disorders? Current Diabetes Reviews, 12(3), 223–230.
pubmed: 26239835
Mallampalli, R. K., et al. (2013). Targeting F box protein Fbxo3 to control cytokine-driven inflammation. Journal Immunology, 191(10), 5247–5255.
Lomonosov, M., et al. (2011). Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis. PLoS One, 6(6), e21165.
pubmed: 21695055
pmcid: 3117880
Zheng, H., et al. (2014). PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer cell, 26(3), 358–373.
pubmed: 25203322
pmcid: 4159622
Pighi, C., et al. (2021). Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Advances, 5(23), 5239–5257.
pubmed: 34625792
pmcid: 9153037
Zou, S., et al. (2018). FBXO31 suppresses gastric cancer EMT by targeting Snail1 for proteasomal degradationubiquitination and degradation of Snail1 by FBXO31. Molecular Cancer Research, 16(2), 286–295.
pubmed: 29117943
Malonia, S. K., et al. (2015). F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress. Proceedings of the National Academy of Sciences, 112(28), 8632–8637.
Liu, J., et al. (2014). F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6). Journal of Biological Chemistry, 289(31), 21508–21518.
pubmed: 24936062
pmcid: 4118112
Chung, F.-Z., et al. (2014). Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin and promotes neuronal differentiation. Journal of Biological Chemistry, 289(41), 28448–28459.
pubmed: 25143387
pmcid: 4192496
Chen, X., et al. (2014). Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell Death & Differentiation, 21(10), 1535–1545.
Peschiaroli, A., et al. (2009). The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene, 28(35), 3157–3166.
pubmed: 19581926
English, J. M., & Cobb, M. H. J. T. I. P. S. (2002). Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences, 23(1), 40–45.
pubmed: 11804650
Sahasrabuddhe, A. A., et al. (2021). A novel FBXO45-Gef-H1 axis controls oncogenic signaling in B-cell lymphoma. Blood, 138(Supplement 1), 711–711.
Correia, S., et al. (2019). The circadian E3 ligase complex SCF (FBXL3+ CRY) targets TLK2. Sci Rep, 9(1), 198.
pubmed: 30655559
pmcid: 6336870
Hart, M., et al. (1999). The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Current Biology, 9(4), 207–211.
pubmed: 10074433
Wei, S., et al. (2007). Thiazolidinediones modulate the expression of β-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor γ. Molecular Pharmacology, 72(3), 725–733.
pubmed: 17569795
Winston, J. T., et al. (1999). The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes & Development, 13(3), 270–283.